155 results about "Abnormal cells" patented technology

The invention relates to an antibody drug conjugate which is shown in a formula (I) and contains two or more bioactive molecules with different action mechanisms, a preparation method of the antibody drug conjugate, and application of the antibody drug conjugate in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to prevention and / or treatment of tumor diseases. # imgabs0 #

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention belongs to the technical field of medical instruments, and discloses a digestive endoscopy diseased region accurate positioning and marking device which comprises a controller, an endoscope hose is fixedly connected to the bottom of the controller, and an instrument insertion opening is formed in the right side of the controller. Through the arrangement of the sleeve, the dye tube, the pressurization air bag and the baffle, after an operator observes a diseased region through the endoscope hose, the operator only needs to align the endoscope hose to the diseased region, and by pressing the pressurization air bag, air in the pressurization air bag enters the dye tube through the inner hose; the baffle can be pushed to rotate outwards under the action of air pressure, meanwhile, methylene blue in the dye tube is sprayed out under the action of air flow, a diseased region is marked, the methylene blue can be absorbed by normal mucous membrane cells, and diseased tissue shows dyeing difference due to abnormal cell function and poor absorption capacity, so that the diseased region is marked. Therefore, the effect of accurate positioning is achieved.

An antibody-drug conjugate as shown in formula I, a preparation method therefor, and a use thereof in prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to a use in prevention and / or treatment of tumor diseases.

The invention relates to an antibody composition for detecting abnormal CTL (cytotoxic T lymphocyte) cells of hemophagocytic syndrome and application of the antibody composition, and the antibody composition comprises a CD2 antibody, a CD3 antibody, a CD4 antibody, a CD5 antibody, a CD7 antibody, a CD8 antibody, a CD56 antibody, a CD57 antibody, a Granzyme B antibody, a Perforin antibody, a TRBC1 antibody and a CD45 antibody. In the technical scheme provided by the invention, key phenotypic characteristics of CTL (Cytotoxic Lymphocyte) can be completely covered by various antibodies aiming at T cell and NK cell surface markers, T large granular lymphocyte markers, cytotoxic granular proteins, T cell receptor constant regions and leukocyte common antigens; wherein the clonality of the CTL cells is judged through the expression level of the TRBC1 antibody, and the cytotoxic function activity of the CTL cells is evaluated through the expression levels of Granzyme B and Perforin.

The embodiment of the application discloses an abnormality detection method and device for cell entering a shell, electronic equipment and a storage medium. The method comprises the following steps: acquiring detection data in the process that a cell entering shell machine drives the cell to enter a battery shell; generating one or more to-be-detected curves according to the detection data; detecting the one or more to-be-detected curves respectively according to historical detection data to obtain a detection result corresponding to each to-be-detected curve; and determining an abnormality result of the cell entering the shell according to the detection result corresponding to each to-be-detected curve. The embodiment of the application can improve the accuracy of the abnormal cell judgment. The above judgment process does not need manual inspection, improves the intelligent degree of the cell detection process, can effectively determine the main abnormal problems in the production process, and can be solved in a targeted manner, thereby improving the accuracy and efficiency of the abnormal detection of the lithium cell entering the shell process.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

A polymeric nanoparticle is disclosed which comprises:(i) at least one disease-associated antigen which is capable of producing a T-cell response, wherein the disease-associated antigen is encapsulated in the nanoparticle;(ii) at least one adjuvant; and(iii) a dendritic cell targeting moiety which is attached to the outer surface of the nanoparticle.Use of the nanoparticle for treating diseases associated with abnormal cell growth or an infection is also disclosed.

The invention discloses a direct counting method and device for detecting the number of fluorescence-labeled rare abnormal cells in a blood sample. Aiming at the problem that direct counting of low-abundance cells is difficult to realize in a conventional blood container by a traditional detection means, the method realizes rapid and direct counting of rare abnormal cells by performing narrow-band filtering, efficient collection and high signal-to-noise ratio detection on a fluorescence signal emitted by a static blood sample. The device comprises a lighting source module, an exciting light and emitted light narrow-band filtering module, a light beam collimation and beam expansion module, a sample bearing module, an emitted light collection and detection module and a data processing and counting module. Accurate counting of the extremely-low-abundance fluorescence labeling abnormal cells can be completed in a conventional transparent container without flow sorting or complex treatment of a blood sample, and the method has the advantages of being easy and convenient to operate, high in detection speed, suitable for clinical screening and the like.

The invention relates to novel cell-binding agent-maytansinoid conjugate having a self-immolative peptide linker and more specifically to conjugates of formula (I). The invention also provides novel maytansinoid compounds of formula (II), (III), (IV) or (V). The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.

The invention discloses an antibody composition for detecting mother cell plasma cell-like dendritic cells. The antibody composition comprises a first group of antibodies, a second group of antibodies, a third group of antibodies and a fourth group of antibodies, the first group of antibodies comprises a CD36 antibody, a CD4 antibody, a CD14 antibody, a CD56 antibody, a CD5 antibody, a CD3 antibody, a CD8 antibody, a CD2 antibody, a CD7 antibody and a CD45 antibody; the second group of antibodies comprises an HLA-DR (Human Leukocyte Antigen-DR) antibody, a CD33 antibody, a CD34 antibody, a CD56 antibody, a CD117 antibody, a CD123 antibody, a CD19 antibody, a CD38 antibody and a CD45 antibody; the third group of antibodies comprises a CD303 antibody, a CD304 antibody, a CD41 antibody, a CD56 antibody, a CD13 antibody, a CD85j antibody, a CD64 antibody, a CD15 antibody and a CD45 antibody; and the fourth group of antibodies comprises TdT, MPO, CD56, cCD3, CD10, cCD22 and CD45 antibodies. The antibody composition can be used for accurately detecting tumor abnormal BPDCN cells.

The present disclosure relates to novel compounds that act as modulators of cereblon (CRBN). The compounds promote CRBN-mediated ubiquitination and proteasomal degradation of oncogenic proteins such as GSPT1 and MYC, thereby suppressing abnormal cell growth. Pharmaceutical compositions containing the compounds and methods of using the compositions for the treatment of cancers, particularly solid tumors, are also provided.

The present disclosure relates to compounds of Formula (I′):and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparation these compounds, compositions comprising these compounds, and methods of using them in the prevention or treatment of abnormal cell growth in mammals, especially humans.

The invention provides a genetic engineering strain and a construction method thereof, the strain is a target gene deleted strain obtained by knocking out a target gene in a rod-shaped bacterial strain, and the target gene is one of minC and minD genes or a gene combination thereof. According to the present invention, the minC and / or minD gene deletion strain is obtained by knocking out the minC and / or minD gene in the rod-shaped bacterial strain, such that cell division abnormality can be caused, chromosome-free small cells are generated, and the small cells have characteristics of biological activity, no chromosome DNA, and no growth or division propagation. The small cells can generate smaller body immune response, and meanwhile, the LPS modified by the small cells can generate smaller cytotoxic reaction, so that side effects can be greatly reduced when the small cells are applied to human or animal bodies.

Disclosed herein is a method for training a network to detect and classify abnormal pathologies in images if cells. Specifically, the network uses a deep framework optimally trained to detect and classify abnormal cervical cells in pap smear images.

The invention discloses a method and a device for judging network access perception degradation, electronic equipment and a storage medium. The method comprises the steps that a first object of a target line is determined, the target line comprises a plurality of first cells, and the first cells are the network coverage range of a communication base station of each high-speed rail station on the target line; determining a third index based on the association degree of the first index and the second index; the first index is a key quality index of each first cell network, and the second index is an index of a network operation state and network technical performance of each first cell; the third index is a first index strongly related to the internet surfing perception of the first object; determining a first index threshold value of the third index, and determining a second object based on the third index and the first index threshold value; the second object is an object with degraded internet access perception in the first object; and determining the distribution condition of the second object in each first cell, and determining an abnormal cell according to the distribution condition. According to the method, the wireless network sensing condition of the high-speed rail line can be accurately judged.

The present application provides a linker, an antibody-drug conjugate, a preparation method therefor and the use thereof in the prevention and / or treatment of diseases related to abnormal cell activity, including but not limited to the prevention and / or treatment of tumor diseases.

The present invention relates to the field of medical therapy of lesions detrimental to a body. The system is capable of treatment with a non-invasive, ionizing kV energy radiation source. Locally focused energy can be used to definitively treat, or as an adjuvant to enhance immune modulators, to eliminate tumors. Distributed external beam entry points produce a significant advantageous dose profile at depth as intersecting beams accumulate in a narrow focus to treat a selected volume. Targeted disease may have enhanced sensitivity to the radiation by taking up an ionizing-radiation, treatment-localizing agent. This increases the effectiveness of an energy dose in the lesion. The pattern of beam output is effectively directed towards a desired location and kV x-rays traveling towards undesired locations, such as healthy tissue, are quenched. Targeting a lesion within the body with volumetrically discrete energy dose deposition can beneficially impact harmful lesions. Aiming the beam at a pathologic target is done while moving an x-ray source mechanically around a patient to distribute surface dose. The purpose of the focused energy deposition is to destroy and disable pathologic physiology, such as malignant masses. More specifically this invention relates to a system, which optimizes delivery of ionizing kV beams to a lesion alone or one containing treatment-localizing agents in higher concentration than the surrounding normal tissues. Thereby an optimal delivery of ionizing radiation becomes more destructive to a mass of abnormal cells upon interaction with the targeted site.

A pyrrolopyrimidine or pyrrolopyridine derivative and its medical use. Specifically, the compound has the structure shown in formula I, has good inhibitory effect on focal adhesion kinase (FAK), and can inhibit its related signal pathways, and can be prepared for treating or preventing diseases related to cancer, pulmonary arterial hypertension, pathological angiogenesis, etc., and can be particularly used for treating diseases caused by excessive or abnormal cell proliferation, such as tumors or cancers.

The present disclosure relates to a Camptothecin compound having anti-tumor activity, a preparation method therefor, and an application thereof. Specifically, the present disclosure relates to a compound as shown below or a pharmaceutically acceptable form thereof, a pharmaceutical composition thereof, a preparation method therefor, and a use thereof. The compound can be used as a drug for treating diseases in abnormal cell proliferation,

The embodiments of the present disclosure provide a method, device, electronic device, storage medium and program product for detecting abnormal cells, which relate to the field of battery technology. The method comprises: determining a cell to be detected; obtaining a plurality of measurement parameters corresponding to a plurality of sequential processes in the cell detection process for the cell to be detected; for each first process, determining the prediction parameters of the first process based on the measurement parameters of the previous process of the first process and the state transition information corresponding to the first process; and determining the abnormal detection results of the cell to be detected based on the differences between the measurement parameters and the prediction parameters corresponding to each first process. The embodiments of the present disclosure effectively detect abnormal cells without puncturing the diaphragm, reduce the missed detection rate of abnormal cell detection, thereby effectively eliminating abnormal cells caused by metal foreign matter and diaphragm defects, and improve the quality and safety of the produced batteries.

This invention relates to the crystalline form (form 7) of the free base of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2H-8,4-(methiminated bridged)pyrazolo[4,3-h][2,5,11]benzoxazadiazetatetracycline-3-carboxynitrile (lorlatinib). The invention also relates to pharmaceutical compositions comprising form 7 and to methods of treating abnormal cell growth in mammals, such as cancer, using form 7 and such compositions.

The application relates to the technical field of image processing, in particular to an abnormal cell screening method and system based on image analysis, which comprises the following steps: acquiring continuous image frames of a staining process, extracting average optical density, integral optical density and chromatin gray standard deviation of sample cells as staining parameters, and acquiring chromatin texture; forming a staining parameter space curve with the change of the staining parameters over time, fitting to obtain a continuous staining curve; aligning and fitting the continuous staining curve with a standard parameter curve calibrated in advance to obtain a coordinate transformation vector; acquiring an image frame after the completion of the staining, performing standardization correction on the staining parameters of the to-be-tested cells by using the coordinate transformation vector to obtain chromatin texture features, and then performing feature comparison and identification on abnormal cells. The application reduces the staining sensitivity difference caused by biological factors such as individual gene expression difference, different cell membrane protein compositions and pH value changes, and eliminates the influence of staining condition difference and equipment difference among different laboratories on the screening result.

The present invention provides a process for the preparation of 1, 4-diazaspiro [5.5] undecan-3-one and analogs thereof, which can be used in the preparation of pharmaceutical compounds, including for the treatment of diseases involving abnormal cell proliferation. Chemical intermediates in the process are also provided.

The invention discloses an application of an inhibitor for targeted inhibition of a COLLAGEN pathway in a drug for treating Alzheimer's disease (AD) related to exposure of micro-nano plastic particles (MNPs). The research shows that the exposure of the MNPs can activate a COLLAGEN signal channel among astrocytes, microglia and neurons, promote COL1A1 / COL1A2-ITGA1 / ITGB1 mediated abnormal cell communication, cause the M1 type polarization of the microglia, the activation of the p38-MAPK channel of the neurons and the deposition of A beta, and further accelerate the progress of AD (Alzheimer's disease). The pathway is blocked by knocking down the ligand COL1A1 in astrocytes, so that neuroinflammation can be remarkably reduced, A beta accumulation can be inhibited, and the cognitive function can be improved. The invention provides a new molecular target for the treatment of the MNPs related AD.

The application relates to an abnormal cell identification method, device, equipment, storage medium and program product. The method comprises the following steps: collecting parameters of multiple dimensions of a battery cluster in a same string loop at each moment during a charging process; the multiple dimensions at least include voltage, internal resistance and temperature; mapping the parameters of the multiple dimensions at each moment to a three-dimensional feature space constructed according to the voltage, the internal resistance and the temperature; determining discrete data points according to density information of each data point in the three-dimensional feature space; and determining a defective cell according to the discrete data points. The method can more comprehensively capture abnormal features of the cell, thereby improving the accuracy of defective cell identification.

This invention discloses a novel application of the RNA-binding protein HNRNPA1 in regulating copper death in synovial fibroblasts of rheumatoid arthritis (RA-FLS). Overexpression of HNRNPA1 recognizes and binds to the m6A modification site of SLC3A2 mRNA, enhancing its transcript stability, restoring the expression of SLC3A2 and copper death-related proteins, reducing MDA levels, increasing copper ion concentration and the activity of antioxidant enzymes SOD and POD, thereby repairing mitochondrial ultrastructural damage, inhibiting abnormal cell proliferation, and inducing apoptosis. Reversal experiments confirmed that knocking down SLC3A2 reverses the above effects, indicating that SLC3A2 is a core downstream target of HNRNPA1-mediated copper death. This invention reveals for the first time the decisive role of the HNRNPA1-SLC3A2-copper death axis in the pathological phenotype of RA-FLS, providing a new target for molecular intervention in rheumatoid arthritis.

Described herein are Methods, systems, compositions, and macromolecule complexes, for detecting, analyzing, evaluating, screening for, prognosing, diagnosing, and / or monitoring, pre-cancerous and cancerous conditions with abnormal cell growth in a patient, including patients having Minimal Residual Disease (MRD).

The present invention provides novel anilino-pyrazole derivatives that are inhibitors of cyclin dependent kinase 2 (CDK2). The invention also provides pharmaceutical compositions comprising the compounds, and methods for their use in the treatment of various conditions, diseases, and conditions associated with or associated with CDK2 activity or associated with abnormal cell growth, such as tumor growth and cancer.

The invention provides a method for automatically detecting abnormal cells in urine cast-off cells, which comprises the following steps of: training an abnormal cell frame selection recognition algorithm, and generating an abnormal cell frame selection recognition model; according to the abnormal cell frame selection recognition model, abnormal cell frame selection recognition of a to-be-tested sample is achieved. The method is suitable for early preliminary diagnosis screening and postoperative reexamination of bladder urothelium carcinoma, has the advantages of early noninvasive detection, convenience in analysis and report, simplicity and standardization in operation, suitability for automatic analysis of instruments and the like, and not only can eliminate non-cell impurities in a complex background, but also can effectively separate overlapped cells, so that the detection accuracy is improved. And a foundation is laid for subsequent single cell analysis.